Awakn Life Sciences announces UK government grant funding to cover 2/3rds of the costs of its Phase III clinical trial for alcohol use disorder (AUD).

Pasithea Therapeutics announces being awarded a research grant of AUD $1 million (US$694,000) for its psychedelics-based research for ALS disease.

Compass Pathways announces that Kabir Nath will replace George Goldsmith as CEO effective August 1, 2022.

Better Life Pharma announces additional funding to study BETR-001 as a treatment for depression, via the Mitacs Accelerate program.

Red Light Holland announces a partnership with platinum-selling rapper, Wiz Khalifa, to launch Red Light Holland’s MISTERCAP brand of psilocybin-based products.

Cybin Inc reports its fiscal year 2022 financial results, including progress on several pipeline initiatives, with a cash balance of CAD$53.6 million as of March 31, 2022.

Numinus announces a pilot program to encourage employers to offer ketamine-assisted psychotherapy to employees as a health benefit.

Better Life Pharma will be presenting an abstract on its lead compound, BETR-001, to the European Neuroscience Societies (FENS) Forum in July.

Numinus Wellness announces the completion of its acquisition of Novamind Inc, with Novamind shareholders receiving 0.84 shares of Numinus per Novamind share.

Cybin Inc announces acquiring a Phase 1 DMT study from Entheon Biomedical, at a purchase price of CAD$1 million plus additional considerations.